NYSE: ANVS · Life Sciences · 7 alerts · CIK 1477845
Share price
$0.7500Close, Nov 16
Market cap
$46.5M
Shares outstanding
62.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Annovis Bio, Inc. filings on SEC EDGAR ↗
Annovis Bio reported a net loss of $41.9 million for the nine months ended September 30, 2026, compared to $19.0 million in the prior year, driven primarily by a significant increase in research and development expenses. The company's cash position decreased to $2.8 million from $19.5 million at the end of 2025, though it raised approximately $30.2 million through equity and warrant issuances during the period.
Annovis Bio reported third quarter 2026 financial results and provided a clinical update on its Phase 3 DUET-AD study for Alzheimer's disease, with a data readout expected in March 2027. The company also highlighted a $21.0 million capital raise from an underwritten public offering intended to fund operations through the upcoming clinical milestones.
Term
Q3 2026
“The third quarter marked a shift in our focus from enrolling patients in DUET-AD to executing the trial and preparing for the first data readout and for filing a New Drug Application (NDA). We now have dates set for last patient, last visit of the 6-month treatment period and for database lock, as well as financing in place to carry us through topline results in March 2027. The team is working very hard to deliver clean data and an on-time readout.”
Maria Maccecchini, PhD, President and CEO of Annovis
Annovis Bio Insider Michael B. Hoffman Buys $5M of Stock
Michael B. Hoffman bought 5,000,000 shares of Annovis Bio, Inc. at $1.00 a share, worth $5M in total on Nov 6, 2026. Shares held after the trade: 8,364,883 (+148.6%).
Annovis Bio entered into an underwriting agreement to raise approximately $21.0 million through a public offering of 19,000,000 shares of common stock and 2,000,000 pre-funded warrants, accompanied by warrants to purchase an additional 21,000,000 shares. The company intends to use the proceeds for the clinical development of its lead compound, Buntanetap, in studies for Alzheimer’s and Parkinson’s disease.
Annovis Bio provided a preliminary estimate of its cash and cash equivalents, which were approximately $2.8 million as of September 30, 2026. The company noted that it has not yet completed its quarterly financial closing processes and the figure is subject to change upon completion of its full interim financial statements.
Annovis Bio stockholders approved an amendment to the 2019 Equity Incentive Plan to increase the number of authorized shares available for issuance. Additionally, stockholders approved a charter amendment to double the company's total authorized common stock from 70 million to 140 million shares.
Annovis Bio received a deficiency notice from the NYSE for failing to maintain a minimum average market capitalization of $50 million and stockholders' equity of $50 million over a 30-day period. The company has 45 days to submit a compliance plan and 9 months to regain compliance to avoid delisting. During this period, the stock will continue to trade under the symbol 'ANVS' with an added '.BC' designation.